Payment overview · 2025
General Payments
$1,137.16
74 reported records · 20 companies
Healthcare provider profile · identity verified
Lisa Bosarge Burch, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MOBILE, AL · NPI 1932107943
Verified facts
What the public records show
CMS Open Payments records show Lisa Bosarge Burch, MD received $1,137.16 in general payments during 2025 across 74 reported records.
AstraZeneca Pharmaceuticals LP accounted for 18.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Kerendia, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 239 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Kerendia by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Mounjaro by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 237 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $210.33 | 18.5% | 11 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $165.68 | 14.6% | 20 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $94.33 | 8.3% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $88.75 | 7.8% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $85.28 | 7.5% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $66.98 | 5.9% | 4 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $59.32 | 5.2% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $58.78 | 5.2% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $52.44 | 4.6% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $46.37 | 4.1% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $38.81 | 3.4% | 2 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $35.58 | 3.1% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $19.32 | 1.7% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $18.35 | 1.6% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.19 | 1.6% | 1 | 2025 |
| AGEPHA Pharma FZ LLC | Unresolved — no canonical attribution shown | $17.70 | 1.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.77 | 1.4% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $15.57 | 1.4% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $15.38 | 1.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.23 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,137.16 | 74 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $146.35 | 7 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $101.65 | 13 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $79.69 | 4 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $79.69 | 4 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $79.69 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $70.94 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $66.98 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $63.98 | 4 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $59.32 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $58.78 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $58.78 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $57.24 | 6 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $55.89 | 6 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $52.44 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $47.41 | 3 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $46.37 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $38.81 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $37.87 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $35.71 | 2 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $35.58 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $19.32 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $18.35 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $18.19 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $17.81 | 1 | 2025 |
Source payment records
|
|||||
| LODOCO Normalized: lodoco |
Drug | AGEPHA Pharma FZ LLC | $17.70 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $16.28 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $15.77 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $15.57 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $15.38 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.64 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $14.64 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.23 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.18 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 239 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 94 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 104 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 237 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
53 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
239 | 50 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
56 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
94 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
104 | 17 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
237 | 40 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
124 | 37 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 747 | 206 |
| Atorvastatin Calcium | Atorvastatin Calcium | 719 | 215 |
| Pantoprazole Sodium | Pantoprazole Sodium | 526 | 161 |
| Levothyroxine Sodium | Levothyroxine Sodium | 514 | 140 |
| Losartan Potassium | Losartan Potassium | 406 | 123 |
| Potassium Chloride | Potassium Chloride | 400 | 127 |
| Metformin Hcl Er | Metformin Hcl | 366 | 104 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 330 | 58 |
| Gabapentin | Gabapentin | 324 | 82 |
| Hydrochlorothiazide | Hydrochlorothiazide | 288 | 81 |
| Omeprazole | Omeprazole | 288 | 83 |
| Furosemide | Furosemide | 270 | 90 |
| Farxiga | Dapagliflozin Propanediol | 239 | 50 |
| Ozempic | Semaglutide | 237 | 40 |
| Trazodone Hcl | Trazodone Hcl | 235 | 60 |
| Meloxicam | Meloxicam | 218 | 59 |
| Metoprolol Succinate | Metoprolol Succinate | 213 | 61 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 206 | 61 |
| Escitalopram Oxalate | Escitalopram Oxalate | 201 | 59 |
| Hydralazine Hcl | Hydralazine Hcl | 200 | 64 |
| Lisinopril | Lisinopril | 197 | 57 |
| Simvastatin | Simvastatin | 192 | 53 |
| Zolpidem Tartrate | Zolpidem Tartrate | 185 | 28 |
| Tramadol Hcl | Tramadol Hcl | 177 | 45 |
| Januvia | Sitagliptin Phosphate | 175 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 168 | 47 |
| Alendronate Sodium | Alendronate Sodium | 154 | 51 |
| Sertraline Hcl | Sertraline Hcl | 137 | 41 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 133 | 36 |
| Tizanidine Hcl | Tizanidine Hcl | 125 | 29 |
| Eliquis | Apixaban | 124 | 37 |
| Carvedilol | Carvedilol | 122 | 37 |
| Clonazepam | Clonazepam | 117 | 24 |
| Allopurinol | Allopurinol | 109 | 29 |
| Valsartan | Valsartan | 106 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 105 | 29 |
| Metformin Hcl | Metformin Hcl | 104 | 32 |
| Mounjaro | Tirzepatide | 104 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 102 | 27 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 100 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 98 | 36 |
| Jardiance | Empagliflozin | 94 | 19 |
| Montelukast Sodium | Montelukast Sodium | 93 | 27 |
| Pioglitazone Hcl | Pioglitazone Hcl | 90 | 26 |
| Ezetimibe | Ezetimibe | 89 | 28 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 89 | 23 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 86 | 21 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 83 | 24 |
| Clonidine Hcl | Clonidine Hcl | 82 | 19 |
| Mirtazapine | Mirtazapine | 75 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 74 | 21 |
| Famotidine | Famotidine | 73 | 24 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 72 | 23 |
| Spironolactone | Spironolactone | 69 | 19 |
| Alprazolam | Alprazolam | 64 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 64 | 19 |
| Fluconazole | Fluconazole | 64 | 28 |
| Donepezil Hcl | Donepezil Hcl | 57 | 17 |
| Xarelto | Rivaroxaban | 56 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 54 | 16 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 54 | 40 |
| Ondansetron Hcl | Ondansetron Hcl | 54 | 28 |
| Linzess | Linaclotide | 53 | 13 |
| Buspirone Hcl | Buspirone Hcl | 50 | 18 |
| Celecoxib | Celecoxib | 50 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 50 | 12 |
| Pregabalin | Pregabalin | 50 | 12 |
| Lorazepam | Lorazepam | 48 | 16 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 48 | 13 |
| Sucralfate | Sucralfate | 47 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 45 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 44 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 44 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 44 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 44 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 44 | 13 |
| Promethazine Hcl | Promethazine Hcl | 44 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 43 | 19 |
| Bupropion Xl | Bupropion Hcl | 42 | 14 |
| Myrbetriq | Mirabegron | 42 | 11 |
| Glimepiride | Glimepiride | 41 | 15 |
| Benazepril Hcl | Benazepril Hcl | 40 | suppressed |
| Atenolol | Atenolol | 39 | 11 |
| Azelastine Hcl | Azelastine Hcl | 39 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 39 | 34 |
| Irbesartan | Irbesartan | 38 | 11 |
| Tamsulosin Hcl | Tamsulosin Hcl | 37 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 35 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 35 | 12 |
| Solifenacin Succinate | Solifenacin Succinate | 34 | 13 |
| Synthroid | Levothyroxine Sodium | 34 | suppressed |
| Temazepam | Temazepam | 33 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 32 | 17 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 31 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 31 | suppressed |
| Aripiprazole | Aripiprazole | 30 | suppressed |
| Primidone | Primidone | 30 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 29 | suppressed |
| Fenofibrate | Fenofibrate | 29 | suppressed |
| Lovastatin | Lovastatin | 29 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 28 | 24 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Azithromycin | Azithromycin | 27 | 23 |
| Ibuprofen | Ibuprofen | 27 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 27 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 23 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Prednisone | Prednisone | 23 | 20 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 22 |
| Topiramate | Topiramate | 23 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 23 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 22 | suppressed |
| Entresto | Sacubitril/Valsartan | 22 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 22 | suppressed |
| Baclofen | Baclofen | 21 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 21 | suppressed |
| Diazepam | Diazepam | 21 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Nystatin | Nystatin | 21 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 21 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 20 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | suppressed |
| Indapamide | Indapamide | 19 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 19 | suppressed |
| Colchicine | Colchicine | 18 | suppressed |
| Klor-Con 10 | Potassium Chloride | 18 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | suppressed |
| Lidocaine | Lidocaine | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Niacin Er | Niacin | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 12 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 15 | suppressed |
| Cefdinir | Cefdinir | 15 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Fluocinolone Acetonide | Fluocinolone Acetonide | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Kerendia | Finerenone | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,137.16 · 74 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, ACCRUFER, AIRSUPRA, AREXVY, COMIRNATY, CONTRAVE, EVENITY, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, JARDIANCE, Kerendia, Korlym, LEQVIO, LODOCO, MOUNJARO, NURTEC ODT, OTEZLA, Ohtuvayre, Ozempic, PREVNAR 20, PROLIA, RELISTOR, REPATHA, Rybelsus, SHINGRIX, SPRAVATO, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, Wegovy, ZAVZPRET, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error